Search Results

12,782 Results for "jennewein biotechnologie gmbh".

Sort By

Deals

Great Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMO

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.

June 13, 2024
·
3 min read
Deals

Jennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market

Jennewein Biotechnologie GmbH agreed to join forces with Chr. Hansen Holding A/S, a leading bioscience company based in Hoersholm/ Denmark , to lead the global market for human milk oligosaccharides (HMOs). Chr. Hansen entered into an agreement to acquire all shares in Jennewein Biotechnologie, the innovation a

September 22, 2020
·
4 min read
Business

Oakwood Chemical Announces Strategic Partnership with EMP Biotech GmbH

Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.

April 9, 2024
·
2 min read
Press Releases

FGK Clinical Research GmbH Highlights 3.5 Years of Success with Flex Databases

October 10, 2024
·
1 min read
Drug Development

HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data

HD Immune GmbH announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.

January 23, 2024
·
2 min read
Press Releases

Dovetail Genomics and Goenomics GmbH Announce Strategic Partnership to Enhance Genome Annotation Services

August 21, 2024
·
4 min read
Press Releases

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

August 15, 2024
·
3 min read
Jennewein Publishes New Results on the Norovirus-inhibiting Effect of Complex Oligosaccharides

Jennewein Biotechnologie GmbH announces the publication of the latest results from its norovirus research program in the Journal of Biotechnology.

May 27, 2020
·
3 min read
Business

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

UroGen Pharma Ltd. today announced a licensing agreement with medac GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers.

January 17, 2024
·
6 min read
News

New4med GmbH Announces First Cases of its novel Basivertebral Nerve Ablation (BVNA)

July 8, 2024
·
2 min read